Citius Pharmaceuticals Issues $1M Promissory Note to Pagoda

Citius Pharmaceuticals ( (CTXR) ) just unveiled an announcement.

On June 2, 2025, Citius Pharmaceuticals issued a $1 million unsecured promissory note to PAGODA RESOURCES, INC, with a 15% annual interest rate, due by December 2, 2025. The note is guaranteed by CEO Leonard Mazur, allowing the company to potentially enhance its financial flexibility and operational capabilities.

The most recent analyst rating on (CTXR) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Citius Pharmaceuticals stock, see the CTXR Stock Forecast page.

Spark’s Take on CTXR Stock

According to Spark, TipRanks’ AI Analyst, CTXR is a Underperform.

Citius Pharmaceuticals’ overall stock score reflects the challenging financial performance and bearish technical indicators. The company’s ongoing losses, reliance on external financing, and negative cash flows are significant concerns. The stock’s downward momentum and negative valuation metrics further contribute to the low score. The biotech firm remains speculative, hinging on future revenue generation and operational improvements.

To see Spark’s full report on CTXR stock, click here.

More about Citius Pharmaceuticals

Citius Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of critical care products, including anti-infectives, cancer care, and unique prescription products.

Average Trading Volume: 297,020

Technical Sentiment Signal: Sell

Current Market Cap: $7.92M

For detailed information about CTXR stock, go to TipRanks’ Stock Analysis page.